ADIM
MRTX

Alpha DNA Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Alpha DNA Investment Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,423
Closed -$628K – 247
2023
Q3 		$628K Buy
+14,423
New +$515K 0.26% 81
2021
Q1 		– Sell
-5
Closed -$1K – 799
2020
Q4 		$1K Buy
+5
New +$1.08K ﹤0.01% 568

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Alpha DNA Investment Management's MRTX Position: Q4 2023 in Review

Alpha DNA Investment Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 14,423 shares — an estimated $628K sold.

Alpha DNA Investment Management first reported a position in MRTX in Q4 2020 and held it in 2 quarters. The position peaked at $628K in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Alpha DNA Investment Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 14,423 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $628K.
  • Alpha DNA Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Alpha DNA Investment Management's Mirati Therapeutics, Inc. Common Stock position peaked at $628K in Q3 2023.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Alpha DNA Investment Management's 13F filing for Q4 2023, filed 12 Feb 2024.